Camille Samuels, MBA, is a Partner at Venrock, a venture capital firm originally established in the late 1960s as the venture arm of the Rockefeller family. Her investment interests span early-stage biotech to medical devices to consumer health. She serves on the board of directors of Unity biotech (UBX), a public longevity company — and is an observer on the board at Corvidia, a private cardiorenal company.
She stepped off the board of RegenXBIO (RGNX) a year after it went public — and from Spirox after its acquisition by Entellus (and Stryker).
Prior to Venrock, Cami spent over a decade as a Managing Director at Versant Ventures, a leading life sciences venture capital firm. While at Versant, Cami seeded Kythera (makers of Kybella) and served on the company’s board through its IPO and eventual sale to Allergan for $2.1B. In addition, she served as a board member or a board observer on many other innovative healthcare companies including: Achaogen (AKAO), Carmenta (acquired by Progenity), Fluidigm (FLDM), Genomic Health (GHDX), Novacardia (acquired by Merck), ParAllele (acquired by Affymetrix), and Syrrx (acquired by Takeda).